Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting
20.5.2021 13:00:00 EEST | Business Wire | Press release
Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial – an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ponatinib (Iclusig®) over a range of three starting doses (45mg, 30mg, 15mg) followed by dose reduction to 15mg with the aim of optimizing efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant to prior tyrosine kinase inhibitor (TKI) therapy – met its primary endpoint.
The trial, sponsored by Takeda and co-funded by Incyte, evaluated treatment in patients with resistant disease, with and without mutations. The results show that the optimal benefit-risk profile for ponatinib in patients with CP-CML was achieved with a starting dose of 45mg/day, and upon response (achieving ≤1% BCR-ABL1IS), dose reduction to 15mg/day. The results also suggest a clinically-manageable safety profile for ponatinib. Data from the OPTIC interim analysis (cutoff date of July 2019), which evaluated 216 patients with a median follow-up of 21 months, were previously reported. The primary analysis (cutoff date of May 2020) evaluated 283 patients with a median follow-up of 32 months. All patients in the OPTIC trial were evaluable for the primary endpoint at the time of this analysis.
“The OPTIC primary analysis reinforces the positive response that is achievable with ponatinib in appropriate patients with CP-CML, and the ability that response-based regimens have to maximize efficacy, while maintaining a manageable safety profile,” said Luca Marini, M.D., Regional Vice President, Head of European Medical Affairs, Incyte. “The OPTIC trial provides additional confirmation on the optimization of ponatinib dosing and reinforces its role as a meaningful treatment option for patients.”
Key findings from the OPTIC primary analysis include:
- The maximum rates of ≤1% BCR-ABL1IS at 12 months, the primary endpoint, were achieved in the 45mg/day starting dose cohort (44.1%), and 73.3% of patients in this cohort maintained response with the dose reduction to 15mg/day. The 30mg/day and 15mg/day starting dose cohorts also demonstrated benefit (29.0% and 23.1% ≤1% BCR-ABL1IS at 12 months, respectively), especially in patients with less-resistant disease and with a T315I mutation.
-
Positive survival outcomes were estimated in all three arms, with an 89.3% 36-month overall survival (OS) probability anticipated for the 45mg starting dose cohort and 73.3% progression-free survival (PFS) anticipated for the same cohort.
- This indicates that the dose-reduction strategy did not impact OS regardless of prior second-generation TKI resistance or the presence of BCR-ABL1 mutations.
- Rates of arterial occlusive events (AOEs) observed at the time of primary analysis (6% overall and 9.6% in the 45mg starting dose cohort) suggest a clinically manageable safety profile.
-
Safety data include:
- Among all study participants (N=283), the most common treatment-emergent adverse events (TEAEs) Grade 3 or greater were thrombocytopenia (27%), neutropenia (17%) and anemia (7%).
- Reported AOEs were 10%, 5% and 3% for the 45mg, 30mg, 15mg/day starting dose cohorts, respectively. Grade 3 or greater AOEs were 5%, 5% and 3% for the 45mg, 30mg and 15mg/day starting dose cohorts, respectively.
- Reported serious AOEs were 4%, 4% and 3% for the 45mg, 30mg, 15mg/day starting dose cohorts, respectively. There were four deaths related to AEs (two sudden deaths and two pneumonia).
“As a physician, I am pleased by the results of the OPTIC trial evaluating patients with resistant CP-CML, who are in need of additional options to improve outcomes,” said Dr. Gianantonio Rosti, M.D., Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST S.r.l.) Istituto di Ricovero e Cura a Carattere Scientifico. “It is encouraging to see the positive benefit-risk profile that can be achieved with ponatinib through a response-based dosing regimen, therefore providing efficacy while also managing the risk for arterial occlusive events.”
Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
About the OPTIC Trial
OPTIC (Optimizing Ponatinib Treatment In CML) is a randomized, dose-ranging Phase 2 trial designed to evaluate three starting doses (15mg, 30mg, 45mg) of ponatinib in patients with resistant chronic-phase chronic myeloid leukemia (CP-CML) or who had documented history of presence of T315I mutation after receiving any number of prior tyrosine kinase inhibitors (TKIs). Dose reduction at response occurred per study protocol. The trial is expected to inform the optimal use of ponatinib in these patients. The primary endpoint of the trial is achieving ≤1% BCR-ABL1 at 12 months. A total of 283 patients were enrolled at clinical sites around the world. Dose reduction at response occurred per study protocol.
For more information about the OPTIC study, please visit https://clinicaltrials.gov/ct2/show/NCT02467270.
About CML
CML – a rare malignancy – is one of four main types of leukemia; it is a result of a genetic mutation that takes place in early, immature versions of myeloid cells, which form red blood cells, platelets and most types of white blood cells. Subsequently, an abnormal gene called BCR-ABL1 forms, turning the damaged cell into a CML cell. CML typically progresses slowly, but it can change into a fast-growing acute leukemia that is hard to treat.
About Ponatinib (Iclusig®) Tablets
Ponatinib (Iclusig®) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.
In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Click here to view the Iclusig EU Summary of Medicinal Product Characteristics.
Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development program for ponatinib and the Company’s chronic-phase chronic myeloid leukemia program generally, its clinical development pipeline and whether or when ponatinib or any development compounds will be approved or commercially available for use in the United States or elsewhere for chronic myeloid leukemia program generally or any other indication, its presentation plans for the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers and development and discovery operations; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020, and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005174/en/
Contact information
Media
Ela Zawislak
+41 21 581 5200
ezawislak@incyte.com
Rachael Remaly Franco
+41 21 581 5203
rremalyfranco@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 17:16:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
